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Background: Lentiviruses such as HIV-1 can be distinguished from other retroviruses by the cyclophilin A-binding
loop in their capsid and their ability to infect non-dividing cells. Infection of non-dividing cells requires transport
through the nuclear pore but how this is mediated is unknown.
Results: Here we present the crystal structure of the N-terminal capsid domain of HIV-1 in complex with the
cyclophilin domain of nuclear pore protein NUP358. The structure reveals that HIV-1 is positioned to allow
single-bond resonance stabilisation of exposed capsid residue P90. NMR exchange experiments demonstrate that
NUP358 is an active isomerase, which efficiently catalyzes cis-trans isomerization of the HIV-1 capsid. In contrast, the
distantly related feline lentivirus FIV can bind NUP358 but is neither isomerized by it nor requires it for infection.
Conclusion: Isomerization by NUP358 may be preserved by HIV-1 to target the nuclear pore and synchronize
nuclear entry with capsid uncoating.
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Lentiviruses are unique amongst retroviruses in that they
can infect non-dividing cells [1]. This attribute is particu-
larly important in the pathogenesis of HIV-1, which
can infect macrophages and CD4+ T cells and establish la-
tency [2]. Other retroviruses, such as the gammaretrovirus
Murine Leukemia Virus (MLV), require mitosis for inte-
gration and productive infection [3]. How lentiviruses
infect non-dividing cells and why gammaretroviruses do
not is unknown. The ability of lentiviruses to infect non-
dividing cells is thought to require use of the nuclear pore
[4]. Depletion of NUP358 (also known as RanBP2), a core
component of the nuclear pore, reduces HIV-1 infectivity,
2-LTR circle formation and proviral integration and leads
to integration site mis-targeting [5-8]. Importantly, sub-
stitution of HIV-1 capsid with capsid from the
gammaretrovirus MLV results in integration site targeting
that phenocopies the effect of NUP358 depletion [5].* Correspondence: lcj@mrc-lmb.cam.ac.uk
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reproduction in any medium, provided the orThe lentiviral capsid protein differs from its
gammaretrovirus counterpart in that it has an extra
loop between helices 4 and 5 of its N-terminal domain
(CAN), called the CypA-binding loop. The presence of
this loop is conserved in all lentiviruses, despite their
considerable divergence and continuous rapid evolution.
The cyclophilin A-binding loop is so-called because it is the
site of interaction with the cellular isomerase, cyclophilin A
(CypA). CypA is a cis-trans prolyl isomerase, which cata-
lyzes bidirectional isomerization of cis and trans forms of
proline. Elegant NMR ZZ-exchange experiments by Bosco
et al. have demonstrated that the lentiviral capsid is a sub-
strate for CypA, suggesting that CypA may catalyze viral
uncoating by isomerization of the capsid G89-P90 peptide
bond [9]. A specific role for isomerization has never been
proven, largely as it has not been possible to mutate either
the virus capsid or CypA in order to preserve binding
but abolish catalysis. However, the CypA-binding loop
is essential for viral infectivity, as mutation of CypA-
binding loop residues G89 or P90 in HIV-1 capsid prevent
efficient replication [6,10,11].
CypA is potently inhibited by cyclosporine A (Cs), which
binds with an affinity of ~1nM [12]. However, the effect oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sufficient to render virus non-infectious [10,13,14]. Fur-
thermore, deletion of the CypA gene in CD4+ T cells
does not prevent HIV-1 replication [15]. This suggests
that whilst the CypA-binding loop is indispensible, CypA
binding is not. Moreover, whilst all lentiviruses have
a CypA-binding loop, they do not all bind CypA or
are affected by Cs inhibition [10,16-20]. For instance,
HIV-2 does not package CypA or require it for efficient
replication [18].
Recent studies have shown that the nuclear pore pro-
tein NUP358 contains a C-terminal cyclophilin domain
(NUP358Cyp) that interacts with the capsid of HIV-1
[6,21]. Here we show that the capsid of HIV-1 targets
NUP358Cyp using its CypA-binding loop and the mechan-
istic consequences of this interaction. The crystal structure
of the complex between NUP358Cyp and the N-terminal
domain of HIV-1 reveals how interaction is maintained
despite significant variation between NUP358Cyp and
CypA. NMR exchange spectroscopy experiments demon-
strate that HIV-1 capsid is a substrate for NUP358Cyp,
which catalyzes its isomerization more efficiently than
CypA. Finally, exchange experiments on both uniformly
and selectively labeled FIV capsid show that FIV is bound
but not isomerized by NUP358Cyp and this lack of isomer-
ization correlates with the inability of FIV to use NUP358
as a co-factor. Together the data suggests that two of the
defining features of lentiviruses – the CypA binding loop
and the ability to infect nondividing cells – are connected
through NUP358. One function of the conserved CypA-
binding loop may therefore be to mediate interaction with
NUP358 and the nuclear pore. Furthermore, interaction
with NUP358 may allow HIV-1 to couple capsid uncoating
with nuclear entry for efficient infection.
Results
The cyclophilin domain from human NUP358 (NUP358Cyp)
shares only 65% amino acid sequence identity with
CypA (Figure 1a). To determine how NUP358Cyp binds
HIV-1 we solved the X-ray crystal structure of HIV-1
CAN in complex with NUP358Cyp at 1.95 Å resolution
(see Additional file 1 for data collection and refinement
statistics). As observed for the recently published structure
of uncomplexed NUP358Cyp [21], despite the sequence
variation between CypA and NUP358Cyp, the structures
of the two cyclophilins are remarkably similar (Cα atoms
show an r.m.s.d of 0.5 Å, Figure 1b). The slot-like binding
site found in CypA is preserved in NUP358Cyp and the
complex of HIV-1 CAN with NUP358Cyp has a similar qua-
ternary arrangement to the CypA complex (Figure 1c,d).
The CypA-binding loop of HIV-1 CAN projects down into
NUP358Cyp and mediates almost all direct interactions. In
comparison to CypA, NUP358Cyp has residues with bulkier
side-chains at the capsid interface, such as K117 and D59(A117 and G59 in CypA), resulting in a more extended
active site surface. This is reflected in a larger buried
surface area in the NUP358Cyp:HIV-1 CAN complex
(610 Å) compared to CypA:HIV-1 CAN (420 Å). This
increased surface area is consistent with the larger entropic
change (and presumed greater solvent release) associated
with NUP358Cyp:HIV-1 CAN versus CypA:HIV-1 CAN
binding (Figure 2b) [5,6,22]. Nevertheless, almost all of
the interactions in the NUP358Cyp complex are physico-
chemically analogous with CypA:HIV-1 interactions. For
instance, the carbonyl of I91 in CAN makes an important
hydrogen bond interaction with CypA via the pyrrole ring
of W121 and with NUP358Cyp via the imidazole side
chain of H121 (Figure 1e,f). Sequence variation between
NUP358Cyp and CypA is also accommodated because
some interactions with HIV-1 CAN are made via main-
chain atoms. An important hydrogen bond interaction
in both NUP358Cyp and CypA occurs between the
side-chain of CAN H87 and the peptide oxygen of residue
71 in the cyclophilins (Figure 1e,f). Despite the physico-
chemical similarities between NUP358Cyp and CypA, there
are functionally relevant structural differences. Cs inhibits
capsid binding to CypA but not NUP358Cyp [6]. The large
cyclic peptide drug is accommodated within the active site
of CypA but superposition of the CypA-Cs complex on
NUP358Cyp reveals that steric clashes preclude binding of
Cs to NUP358Cyp (Figure 1g,h).
Subsequent to our previously published binding data
between HIV-1 CAN and NUP358Cyp [6], we identi-
fied conditions that allowed higher concentrations of
NUP358Cyp to be achieved. This allowed us to repeat
the ITC binding between HIV-1 CAN and NUP358Cyp
using significantly higher protein concentrations than
previously. This gave binding data with a much stronger
signal and consequently a more accurate fit, resulting in
a revised Kd of 94 μM (Figure 2b). This is similar to the
affinity measured by Lin et al. for the same interaction
(Kd ~ 200 μM) [21].
Previous analysis of codon-specific selective pressures
has revealed that NUP358Cyp is under positive selec-
tion, consistent with its role as a viral host co-factor [6].
In particular, it was found that residue 61 has diverged
from ancestral CypA such that it no longer encodes a
methionine but rather a valine, leucine or isoleucine
(Figure 2a). The importance of residue 61 was demon-
strated by reversing this change in human NUP358Cyp
(V61M), which was sufficient to abolish interaction
with HIV-1 in a cellular TRIM-NUP358 assay [6]. Analysis
of the HIV-1 CAN:NUP358Cyp structure reveals that
residue 61 is located at the center of the binding site,
almost directly under CAN P90 (Figure 2b). However,
the presence of a methionine residue at this position is
not itself sufficient to prevent HIV-1 CAN binding, as






Figure 1 HIV-1 CAN:NUP358Cyp complex. (a) Sequence alignment of NUP358Cyp with CypA (conserved regions are shaded and in bold).
(b) Structural alignment of NUP358Cyp (yellow) from our structure with CypA (gray) from the HIV-1 CAN:CypA structure (pdb 1AK4 [23]. (c) HIV-1
CAN (green) bound to CypA (molecular surface; gray) (pdb 1AK4 [23]). (d) HIV-1 CAN (green) bound to NUP358Cyp (molecular surface; yellow).
(e) Detailed view of interactions between the CypA-binding loop of HIV-1 CAN (green ball-and-stick) and CypA (gray). (f) Detailed view of
interactions between the CypA-binding loop of HIV-1 CAN (green ball-and-stick) and NUP358Cyp (yellow). NUP358Cyp residues are numbered
according to the equivalent CypA numbering. (g-h) Structure of CypA:Cs complex (2RMA [24]) (g) or model where NUP358Cyp has been
substituted for CypA (h). Cs is in green.




Figure 2 (See legend on next page.)
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Figure 2 Co-operative NUP358 residues determine HIV-1 capsid binding. (a) Sequence alignment of NUP358Cyp from primates and other
mammals. Residues at position 61 and 113 are highlighted. (b) ITC traces for HIV-1 CAN binding to NUP358Cyp mutants. The location of mutated
residues are indicated in the figures below each trace, with residues 61 and 113 shown as space-filling spheres. CypA is indicated in gray and
NUP358Cyp in yellow. (c) Structural alignment of CypA (gray) from HIV-1 CAN:CypA complex 1AK4 with HIV-1 CAN:NUP358Cyp (yellow). The
CypA-binding loop from HIV-1 CAN is shown in green. Divergent residues in proximity to the binding site are indicated.
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ing position 61 reveals that it is within 4 Å (Cβ-Cβ) of resi-
due 113, which uniquely in humans is a valine, having
diverged from the ancestral phenylalanine found in CypA
and other species’ NUP358Cyp (Figure 2a). The residue at
position 113 has been shown to be important for the
interaction of both CypA and NUP358Cyp with HIV-1
CAN, as mutation of this residue to the bulky aromatic
residue tryptophan in either cyclophilin prevents binding to
HIV-1 CAN [21,26]. To determine whether these two resi-
dues, 61 and 113, are acting cooperatively to dictate HIV-1
CAN binding, we made combinations of these mutations
on the background of NUP358Cyp and tested their binding
to HIV-1 CAN by ITC (Figure 2b). In agreement with
the published TRIM-NUP358 assay [6], we found that
V61M was sufficient to abolish interaction with HIV-1
CAN. In contrast, mutation V113F preserves HIV-1 bind-
ing. Moreover, when the V61M mutation is made together
with V113F (V61M/V113F) then binding is also preserved.
Thus V61M abolishes binding of HIV-1 to NUP358Cyp
because a methionine at position 61 is tolerated when
position 113 is a phenylalanine (as in CypA) but not when
it is a valine (as in NUP358Cyp). The reason for this
sensitivity to particular combinations at positions 61
and 113 is likely due to the fact that these residues
form the core of the hydrophobic pocket into which CAN
P90 binds (Figure 2c). Intriguingly, only in humans has
NUP358Cyp acquired the F113V mutation (with respect to
ancestral CypA). In other primate species, canines and ro-
dents, F113 is conserved. Mutation M61V pre-dates F113V,
but had human NUP358Cyp acquired its F113V mutation
on an ancestral M61 background then HIV-1 would not be
able to bind NUP358Cyp in human cells.
As HIV-1 capsid is not the natural ligand for NUP358Cyp,
we used the complexed structure to assess the specificity
of the interaction. If there were selection pressure on the
virus to maintain the interaction we would expect a higher
degree of shape complementarity than if it were serendip-
itous cross-reaction. Using the CCP4 program ‘SC’, we
calculated a surface complementarity score (Sc) for the
HIV-1 CAN:NUP358Cyp complex of 0.78. As typical
protein:protein interactions have Sc scores from 0.6-0.8
[27], this indicates that the interaction is highly specific.
Calculation of Sc scores from HIV-1 CAN:CypA complexes
gives similar scores (~0.8). Whilst the sequence differences
between NUP358Cyp and CypA have not significantly
altered its conformation, NUP358Cyp does have alteredsurface electrostatics (Additional file 2). NUP358Cyp
differences with respect to CypA in and around the active
site such as K76Q and R148P mean that NUP358Cyp has
a negatively charged surface at physiological pH (pI of 5.9)
compared to CypA, which is positively charged (pI of 7.7).
However, the positively charged key catalytic residue R55
is conserved in both molecules and adopts a comparable
position in their active sites (Figure 1e,f). The conservation
of R55 positioning and its proximity to CAN P90 suggested
to us that R55 may hydrogen bond with the peptide oxygen
of P90 and lower the activation energy for cis-trans prolyl
isomerization.
The cyclophilin domain of NUP358 has been shown to
be an active isomerase, although it possesses much weaker
catalytic activity than CypA when tested using a synthetic
proline-containing peptide substrate [21]. So far, the only
biological role assigned for NUP358Cyp has been to facili-
tate the interconversion of thermodynamically or kinetic-
ally trapped isoforms of red/green opsin in cone cells via
cis-trans prolyl isomerization of proline residues within
opsin [28]. Given that CypA has been shown to isomerize
HIV-1 capsid [9], we investigated whether CAN is also a
substrate for NUP358Cyp using NMR ZZ-exchange spec-
troscopy. Previous work by Bosco et al. and Eisenmesser
et al. has shown that ZZ-exchange is an effective way
of measuring CypA isomerization under steady state
conditions [9,29]. 2D 1H-15N ZZ-exchange data on uni-
formly 15N-labeled CAN were collected in the presence
of NUP358Cyp and CypA and compared to intrinsic
ZZ-exchange of 15N-labeled CAN alone. 1H-15N correlation
spectra require amide protons and therefore proline resi-
dues (such as P90) are not detected. However, the adjacent
residue, G89 is characterised by two 1H-15N correlation
peaks indicating that the proceeding proline must exist in
both cis and trans forms (Figure 3a-c). These “auto” peaks
are detected in the absence or presence of NUP358Cyp or
CypA, respectively. An estimation of the cis/trans distri-
bution at equilibrium using 1H-15N correlation (HSQC)
spectra revealed that ~14% of the capsid G89-P90 bond
exists in cis and ~86% trans, as previously observed [9].
The introduction of a variable mixing period in ZZ-
exchange experiments enables inter-conversion between
the cis and trans isomers resulting in the mixing time
dependent build up of “exchange” peaks which connect
“auto” peaks in a distinct pattern. For CAN alone, there
is no detectable magnetization transfer between the two





Figure 3 NUP358Cyp catalyses cis-trans isomerization of HIV-1 CAN. (a-c) 2D 1H-15N ZZ-exchange spectra of HIV-1 CAN focused on Gly89,
without enzyme (a), in the presence of NUP358Cyp (b) or CypA (c). Gly89 cis,trans 1H,15N correlation or “auto” peaks are labeled and are the
result of cis and trans forms of the proceeding Pro90 residue being populated at equilibrium. Addition of either NUP358Cyp or CypA yields
exchange peaks that connect cis and trans auto peaks (broken lines). The cis exchange peak appears at the same 1H (15N) chemical shift position
as the trans auto peak and vice versa. Note, that the trans exchange peak is largely obscured by additional signals in the spectra. (d-e) The
intensities of both auto and exchange peaks vary as a result of the ZZ-mixing time (Tm). Fits of CypA (d) and NUP358Cyp (e) yield exchange
constants of 4.3 and 12.1 s-1 respectively.
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isomerization is very slow, with an exchange rate < 0.1 s-1.
However, addition of catalytic amounts (1:10 molar ratio)
of either CypA or NUP358Cyp results in the rapid build-up
of intense exchange peaks, indicating fast cis-trans
isomerization is now taking place (Figure 3b,c). These
experiments unambiguously confirm HIV-1 capsid as a
substrate for NUP358Cyp isomerization.
In order to determine the efficiency of NUP358Cyp isom-
erization of HIV-1 capsid and compare this to CypA, we
analysed mixing time dependent “exchange” and “auto”
peak intensities, as previously described [9]. We found
that CypA catalyzed capsid isomerization with a rate of
4.3 ± 2.3 s-1 (Figure 3d) (similar to previously described
values of 6.6 ± 2.4 [30]). Under similar conditions,
NUP358Cyp catalyzed HIV-1 isomerization between 2–3
times faster than CypA, at a rate of 12.1 ± 3.4 s-1 (Figure 3e).
This data suggests that, despite the weaker interaction,HIV-1 capsid might be a better substrate for isomerization
by NUP358Cyp than by CypA. Capsid isomerization has
been hypothesized to act as a stimulus for viral uncoating
[9,31]; therefore it is possible that an increase in the rate
of capsid isomerization due to NUP358Cyp might act as a
trigger for HIV-1 uncoating and allow nuclear entry.
Finally, we attempted to address whether NUP358Cyp-
mediated isomerization is important for viral infection.
Despite extensive study, no HIV-1 mutants have been
found which bind NUP358 or CypA but are not isomerized.
Therefore, we decided to investigate the capsid of a natur-
ally occurring divergent lentivirus. The CypA-binding loop
is present in all lentiviruses but the sequence varies exten-
sively, particularly between primate and feline lineages. To
determine whether there is any separation of binding and
isomerization in the feline lineage we extended our study to
look at feline immunodeficiency virus (FIV). FIV can bind
to CypA [32] but has a very different loop sequence to
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‘GP’ motif. Nevertheless, as for HIV-1, P90 has been shown
to be an important residue for interaction of FIV CAN
with CypA [32]. Testing by ITC revealed that FIV also
binds human NUP358Cyp (Figure 4a). Next we examined
15N-labeled FIV CAN to establish whether it is isomerized
by human NUP358Cyp. Unlike with HIV-1, addition
of catalytic amounts of NUP358Cyp did not lead to
any significant peak changes in variable mixing period
ZZ-exchange experiments, suggesting that FIV is not
isomerized by human NUP358Cyp (Figure 4b). The
FIV spectrum around R89 is densely populated, so to
rule out the possibility that isomerization peaks are
masked, we expressed and purified CAN selectively labeled
with 15N arginine. There are six arginine residues in FIV
CAN and six peaks are observed in the HSQC spectra from
the selectively labeled protein (Figure 4c). Furthermore,
these peaks overlay well with the equivalent peaks
from the uniformly labeled protein. With this system,
we re-examined ZZ-exchange upon addition of human
NUP358Cyp. As can be clearly seen, there is no change in
any of the arginine residues, including R89 (Figure 4c).
Taken together, the data show that FIV is bound but not
isomerized by human NUP358. Finally, we compared infec-
tion of HIV-1 and FIV attenuated GFP virus in HeLa cells
stably transduced with either empty vector or vector encod-
ing shRNA against NUP358 or TNPO3 (Figure 4d). As pre-
viously shown, depletion of NUP358 or TNPO3 inhibits
infection of HIV-1 [6-8,33,34]. However, depletion of these
proteins has no effect on FIV infection (Figure 4d) [34,35].
It is noteworthy that, in FIV, loss of NUP358 isomerization
correlates with lack of dependence on this co-factor for in-
fection. Moreover FIV infection also occurs independently
of TNPO3 (Figure 4d) [34,35], a nuclear transport factor
that is involved in the same HIV-1 nuclear entry pathway
as NUP358 [6,34] and whose subcellular localization has
been shown to be affected by NUP358 depletion [36].
Discussion
Nuclear pore protein NUP358 was identified as a candidate
co-factor for HIV-1 replication in two independent siRNA
screens [37-39]. Depletion of NUP358 has subsequently
been shown to inhibit HIV-1 replication and interfere with
targeting viral integration into the host genome [5-8]. Here
we have provided a structural basis for HIV-1 CAN:
NUP358Cyp interaction. Furthermore, we have shown
that NUP358Cyp interaction, but not isomerization, is
conserved by FIV, a virus that does not require NUP358
for infection. This is significant as it provides the first dis-
tinction between binding and isomerization of a lentiviral
capsid by a cyclophilin, and may shed light on the role of
NUP358 interaction in lentiviral infection.
Recent microscopy data have shown that intact HIV-1
capsid cores can dock at the nuclear pore [40] and thatthis perinuclear localization is dependent on NUP358
[8]. NUP358 is a large, multidomain protein that forms
the cytoplasmic filaments of the vertebrate nuclear pore
complex [41,42]. There are eight copies of NUP358 at the
nuclear pore, which form a ring of ~35-50 nm filaments
on the cytoplasmic side of the nuclear pore and project
into the cytoplasm [43,44]. NUP358 contains four RanGTP
binding domains, two Zinc fingers, several FG repeats and
a C-terminal cyclophilin domain [41,45]. The C-terminal
cyclophilin domain, which is bound by HIV-1 CAN, is
found at the tips of the cytoplasmic filaments, as evidenced
by the fact that deletion of this domain still allows NUP358
to localize to the nuclear membrane, and expression of this
domain on its own is not sufficient to localize to the nu-
clear membrane [8,21]. The direct interaction we observe
between NUP358Cyp and the HIV-1 capsid provides one
explanation for how HIV-1 cores dock at the nuclear pore,
without precluding the possibility that other domains of
NUP358 might cooperate to facilitate nuclear docking,
perhaps via non-specific interactions of HIV-1 cores
with FG repeats [8]. Use of the CypA-binding loop by
HIV-1 to target the virus to the nuclear pore via interaction
with the cyclophilin domain of NUP358 also provides
an explanation for the key observation that substitution
of HIV-1 CA with MLV CA prevents HIV-1 infection of
non-dividing cells [46].
NUP358 plays an important role in nucleocytoplasmic
transport, being the site of interaction with Ran (the small
GTPase that regulates nucleocytoplasmic transport by
proteins of the karyopherin β family [47]), SUMO-modified
RanGAP (the mammalian RanGTPase-activating protein
that is highly concentrated at the cytoplasmic side of the
nuclear pore complex [48,49]), and the export receptor
CRM1 [50]. Nup358 has also been suggested to act as a
platform to recruit import receptors to pre-bound cargos,
as cellular substrates DBC-1 and DMAP-1 have been
shown to directly bind to NUP358 and be transported by
importin α/β [51]. Therefore, recruiting to the nuclear pore
via CA interaction with NUP358 may allow HIV-1 access
to importin or transportin routes into the nucleus and drive
integration into actively transcribing regions of the genome.
The presence of intact capsid at the nuclear pore has led
to the suggestion that capsid uncoating may take place after
pore docking. This hypothesis is attractive, as last-minute
uncoating provides several potential advantages for the
virus. First, it allows the viral proteins, enzymes and nucleic
acids to be kept together – increasing enzymatic efficiency
and ensuring that components are at the right place at the
right time. Second, late uncoating means that the virus gen-
ome is protected within its capsid for as long as possible
from the cytosol of the host cell. The host cytosol is a
dangerous place for the virus genome, as it contains
pattern recognition receptors such as the RIG-I-like
receptors and AIM-2-like receptors which recognize
bc
a d
Figure 4 (See legend on next page.)
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Figure 4 FIV uncouples binding and isomerization by NUP358. (a) ITC trace of NUP358Cyp interaction with FIV CAN. (b) Overlay of 2D
1H-15N ZZ-exchange spectra of FIV CAN in the presence of NUP358Cyp at 3 and 197 ms mixing times. Zoomed-in views of the peaks
corresponding to G87 and R89 are also shown. The cross-hairs indicate where exchange peaks would be situated, if cis-trans isomerization took
place. (c) Overlay of uniformly 15N-labeled and selective 15N-Arg labeled FIV CAN. Spectra of selective 15N-Arg labeled FIV CAN are also shown in
panels on the right in the absence (top) and presence (bottom) of human NUP358Cyp. (d) Upper: Western blots showing depletion of NUP358
or TNPO3 in HeLa cells using antibodies against NUP358, TNPO3 or β-Actin as loading control [6]. Lower: VSV-G pseudotyped GFP-encoding HIV-1
or FIV infection of HeLa cells and HeLa cells expressing scrambled control (shC) or NUP358 or TNPO3 specific shRNA [6,33] (mean of three
independent viral doses, error bars show standard deviation). Titers are plotted as infectious units per ng of reverse transcriptase activity. Data are
representative of two independent experiments.
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such as APOBEC3G [53]. However, by maintaining an
intact capsid inside the cell, the virus becomes vulnerable
to innate capsid-targeting restriction factors such as
TRIM5α and, in certain primate species, TRIMCyp
[22,54-56]. A problem with the late uncoating model is
the question of how uncoating is triggered. Elegant ex-
periments using cyclosporine inhibition of TRIMCyp
restriction suggest that uncoating may be facilitated by
reverse transcription, since inhibition of reverse tran-
scription delays the process of uncoating [57]. The rate
of this process may be linked to the time required for
virus to recruit to the pore, ensuring that uncoating oc-
curs immediately prior to nuclear entry. Alternatively, it
has been suggested that isomerization of capsid by CypA
may be the trigger for viral uncoating [9], but if this is the
case then uncoating would be expected to occur as soon
as the capsid encounters the cytoplasm upon cell entry.
We have shown that NUP358Cyp is an active prolyl isom-
erase, capable of catalyzing the isomerization of HIV-1
capsid more efficiently than CypA. It is therefore possible
that by interacting with NUP358Cyp, HIV-1 can both re-
cruit to the pore and ensure uncoating occurs at the right
place at the right time. Unfortunately, without the ability
to make mutations in the capsid of HIV-1 that preserve
binding but abrogate isomerization it is not possible to
directly test this hypothesis. However, we have shown that
FIV can be used as a model virus in which binding to
human NUP358Cyp occurs but isomerization does not.
It is tempting to speculate that the inability of FIV to
be isomerized by NUP358Cyp may explain why it does
not use NUP358 and associated transportin TNPO3
for nuclear entry and infection in human cells [34,35].
However, further experiments on fully infectious FIV in
spreading infection of primary feline cells will be necessary
to comprehensively unpick its nuclear import pathway.
On the basis of our crystallographic and NMR data, we
speculate that interaction between capsid and NUP358 may
allow HIV-1 to recruit to the nuclear pore and synchronize
uncoating with nuclear entry. This may help to explain why
depletion of NUP358 affects HIV-1 infectivity and integra-
tion targeting, why HIV-1 capsids dock at the pore and
why all lentiviruses preserve their CypA-binding loops.Conclusions
We have solved the crystal structure of HIV-1 CAN in
complex with the cyclophilin domain of nuclear pore pro-
tein NUP358, revealing how HIV-1 may target itself to the
nuclear pore during infection. Accompanying NMR data
also reveal that NUP358Cyp isomerizes HIV-1 CAN more
efficiently than CypA but is unable to isomerize capsid from
the distantly related FIV. This result may be significant
because FIV, unlike HIV-1, does not require NUP358 for
infection. Our data suggest that isomerization by NUP358
may be preserved by HIV-1 both to target the nuclear pore
and synchronize nuclear entry with capsid uncoating.
Methods
Protein expression and purification
HIV-1 M-group (NL4-3) N-terminal capsid domain
(HIV-1 CAN; residues 1–146 (Gag residues 133–278);
AAB60571.1) was cloned into a tagless expression vector,
and FIV N-terminal capsid domain (FIV CAN; residues
1–139 (Gag residues 136–274); AAU12277.1), human
CypA (P62937.2) and the cyclophilin domain from human
NUP358 (residues 3057–3224; P49792.2) were cloned into
an expression vector containing an N-terminal His6-tag.
All proteins were expressed in E. coli C41(DE3) cells,
induced with 100 μM IPTG at OD600 of 0.8 and incubated
overnight at 20°C. Uniformly 15N-labeled CAN domains of
HIV-1 or FIV were expressed in E. coli in K-MOPS buffer
supplemented with 20 mM 15NH4Cl as the sole source
of nitrogen. Selectively labeled FIV CAN was prepared by
expressing in the presence of 15N-arginine (15N-R(N4))
or with 15N and 13C sources. HIV-1 CAN was purified
as described [58]. His6-tagged proteins were purified
using Ni-NTA beads (Qiagen) and gel-filtration chro-
matography in 75 mM Tris pH 8.0, 50 mM NaCl,
1 mM DTT. All mutant proteins were expressed and
purified as per the wild-type proteins.
Crystallization and structure determination
Crystals of HIV-1 CAN in complex with NUP358Cyp
were grown in the following conditions: protein solution
(0.55 mM each of HIV-1 CAN and NUP358Cyp in 10 mM
potassium phosphate pH 7.4, 1 mM DTT) was mixed with
reservoir solution (23% v/v PEG 4000, 23% glycerol, 8.5%
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tetrahydrochloride, 100 mM glycine) in a 1:1 mix. Drops
(total volume 400 nl) were set up in sitting drop format
and the plates incubated at 17°C. Crystals grew within
48 h, to a size of 0.14 mm x 0.04 mm x 0.04 mm. Crystals
were flash-frozen in liquid nitrogen, and data collected at
beamline ID14-1 at the ESRF (Grenoble, France). Data
were processed using MOSFLM [59] and the CCP4 suite
[60]. All structures were determined by molecular re-
placement in Phaser [61], using the structure of HIV-1
CAN from 1AK4 [23] as a search model. Model build-
ing was performed using Coot [62] and refinement was
carried out using REFMAC5 [63]. Model validation
was performed using MolProbity [64]. Crystallization
and refinement statistics are shown in Additional file 1.
Figures were prepared using PyMOL.Isothermal titration calorimetry
Samples were dialysed against 50 mM potassium phosphate
pH 7.4, 100 mM NaCl, 1 mM DTT. Protein concentrations
were determined by absorbance at 280 nm. ITC experi-
ments were carried out using a MicroCal ITC200 calorim-
eter, with NUP358Cyp (typical concentration 2.5 mM) in
the syringe and HIV-1 CAN (typical concentration 0.2 mM)
in the cell. Experiments were conducted by titrating capsid
(syringe) into cyclophilin (cell) at 15°C. Data were analysed
using MicroCal Origin 7.0 implementing a simple one set
of binding sites model.Protein assignments
The spectra of 15N,13C-His6-FIV CA
N and 15N,13C-HIV-1
CAN were acquired on a Bruker 600 MHz spectrometer at
298 K using a final concentration of 500 μM (FIV) and
330 μM (HIV-1) protein sample. Data processing was
performed in TopSpin 3.0 (Bruker, Karlsruhe).2D 1H-15N Heteronuclear (ZZ) Exchange Spectroscopy
For all NMR experiments, proteins were dialysed against
50 mM potassium phosphate pH 6.5, 1 mM DTT. Capsids
were used at 12-fold excess concentration over CypA or
NUP358Cyp as previously described [9,30]: 430 μM CAN
and 35 μM CypA or NUP358Cyp, or 430 μM CAN
only. All NMR samples contained 5% D2O. 2D
1H-15N
heteronuclear (ZZ) exchange was performed as previously
described [65] using published models [9,30]. The experi-
ments were performed on a Bruker 800 MHz spectrometer
at 298 K using an in-house written pulse program with
mixing times collected in a randomised order. The first
time-point was acquired twice to assess the error. The data
was processed in TopSpin 3.0 (Bruker, Karlsruhe) after ana-
lysis in Sparky (T. D. Goddard and D. G. Kneller, University
of California, San Francisco).Infection assays
VSV-G pseudotyped vectors derived from HIV-1 and
FIV have been described, as has their preparation by 293 T
transfection [66]. Viral doses were measured by reverse
transcriptase enzyme linked immunosorbant assay (Roche).
Viral vector infection assays using VSV-G pseudotyped viral
vectors encoding GFP were analyzed by enumerating
the number of green cells 48 hours post infection by
flow cytometry. Stable HeLa cell clones expressing NUP358
specific or TNPO3 specific short hairpin RNA (shRNA)
from MLV vector pSIREN RetroQ (Clontech) have been
described [6]. Scrambled control shRNA (shC) is a mis-
match against TNPO3, and is described in [33].
Protein Data Bank accession number
Coordinates for the HIV-1 CAN:NUP358Cyp complex
crystal structure have been deposited into the RCSB Protein
Data Bank with the accession code 4LQW.
Additional files
Additional file 1: Table of data collection and refinement statistics.
Additional file 2: Surface electrostatics of NUP358Cyp and CypA.
Electrostatic surface potential of NUP358Cyp and CypA, in complex with
HIV-1 CAN (yellow sticks) (CypA:HIV-1 CAN pdb 1AK4) as calculated by
APBS (Adaptive Poisson-Boltzmann Solver). Blue represents a positive
charge and red a negative charge. Scaled from −20 to +20 kT e−1.
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